Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Anti-Human TREM2 Antibody (AL2p-58)

Catalog #:   DHJ69202 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHJ69202

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Target

Triggering receptor expressed on myeloid cells 2, Triggering receptor expressed on monocytes 2, TREM-2, TREM2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NZC2

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

AL2p-58

Data Image
References

TREM2 Hit Discovery Using TRIC Technology: A Proof-of-Concept High-Throughput Screening Approach., PMID:40501992

Trem2 regulates microglial migratory responses via type I interferon signaling during photoreceptor degeneration., PMID:40468324

PET imaging of TREM2 in amyloid-beta induced neuroinflammation., PMID:40434494

Targeted Reprogramming of TREM2-Positive Macrophages and MRI-Guided Immune Monitoring in Colorectal Cancer Using CSF1R@Mn@MPDA-Antitrem2 Nanoplatform., PMID:40417930

Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant Alzheimer´s mouse model., PMID:40405265

The potential and challenges of TREM2-targeted therapy in Alzheimer's disease: insights from the INVOKE-2 study., PMID:40353063

Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers., PMID:40166927

Choroidal Neovascularization Is Suppressed With Activation of TREM2 in Mononuclear Phagocytes-Brief Report., PMID:40143815

Antibody-induced TREM2 ectodomain shedding inhibits TREM2 signaling in macrophage., PMID:40138757

Acute TREM2 inhibition depletes MAFB-high microglia and hinders remyelination., PMID:40131948

TREM2 scFv-Engineering Escherichia coli Displaying Modulation of Macrophages to Boost Cancer Radio-Immunotherapy., PMID:40103438

IL-33-Induced TREM2+ Macrophages Promote Pathological New Bone Formation Through CREG1-IGF2R Axis in Ankylosing Spondylitis., PMID:40091508

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer., PMID:40081941

Pro-Fibrotic Macrophage Subtypes: SPP1+ Macrophages as a Key Player and Therapeutic Target in Cardiac Fibrosis?, PMID:40072075

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease., PMID:40050704

Biological signatures in the Alzheimer's continuum discriminate between diagnosis-related and -unrelated associations to ATN categories., PMID:40046342

TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity., PMID:39971937

Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism., PMID:39891235

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma., PMID:39709141

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology., PMID:39676023

Exosomes derived from TREM-2 knocked-out macrophages alleviated renal fibrosis via HSPa1b/AKT pathway., PMID:39657110

Soluble TREM2 drives triple-negative breast cancer progression via activation of the AKT pathway., PMID:39672020

The Challenges of Modulating Neuroinflammation in Alzheimer's Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies., PMID:39663111

Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease., PMID:39559879

Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice., PMID:39531316

Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease., PMID:39530260

Targeting TREM2 signaling shows limited impact on cerebrovascular calcification., PMID:39467636

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease., PMID:39444037

Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease., PMID:39434125

PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antibodies., PMID:39431020

Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model., PMID:39353433

Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining., PMID:39333507

Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond., PMID:39194679

Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease., PMID:39177331

Therapeutic Spp1 silencing in TREM2+ cardiac macrophages suppresses atrial fibrillation., PMID:39149373

Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism., PMID:39090679

Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?, PMID:39080712

Associations between Microglia and Astrocytic Proteins and Tau Biomarkers across the Continuum of Alzheimer's Disease., PMID:39062786

Multimerization of TREM2 is impaired by Alzheimer's disease-associated variants., PMID:39032157

Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma., PMID:38948071

Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor., PMID:38849345

Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis., PMID:38830764

Mapping Endothelial-Macrophage Interactions in Diabetic Vasculature: Role of TREM2 in Vascular Inflammation and Ischemic Response., PMID:38798611

Distinct roles of TREM2 in central nervous system cancers and peripheral cancers., PMID:38788719

Microglia, Trem2, and Neurodegeneration., PMID:38769824

Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report., PMID:38695172

Modulation of hippocampal protein expression by a brain penetrant biologic TNF-α inhibitor in the 3xTg Alzheimer's disease mice., PMID:38500108

sTREM2 Differentially Affects Cytokine Expression in Myeloid-Derived Cell Models via MAPK-JNK Signaling Pathway., PMID:38392305

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma., PMID:38372949

Microglia at sites of atrophy restrict the progression of retinal degeneration via galectin-3 and Trem2., PMID:38289348

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Anti-Human TREM2 Antibody (AL2p-58) [DHJ69202]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only